Literature DB >> 20190184

Human liver expression of CYP2C8: gender, age, and genotype effects.

Suresh Babu Naraharisetti1, Yvonne S Lin, Mark J Rieder, Kristin D Marciante, Bruce M Psaty, Kenneth E Thummel, Rheem A Totah.   

Abstract

Research investigating CYP2C8 as a drug-metabolizing enzyme has gained momentum over the past few years. CYP2C8 is estimated to oxidatively metabolize approximately 5% of therapeutically prescribed drugs. It is polymorphically expressed, and several single nucleotide polymorphisms have been identified with varying effects on the clearance of CYP2C8 substrates. However, the human liver expression of CYP2C8 and effects of genetic variation, age, and gender on mRNA and protein levels have not been fully explored. In this report, interindividual variation in CYP2C8 mRNA and protein expression in 60 livers from white individuals was examined. The livers were genotyped for CYP2C8*3 and CYP2C8*4 polymorphisms. The effects of genotype, age, and gender on hepatic CYP2C8 expression and the correlation of CYP2C8 mRNA expression with CYP3A4 and other CYP2C members were evaluated. The mean +/- S.D. protein levels in CYP2C8*1/*1 livers was 30.8 +/- 17.5 pmol/mg protein, and a trend for decreased protein levels was observed for CYP2C8*1/*4 livers (15.8 +/- 9.7 pmol/mg, p = 0.07). The mean expression levels of CYP2C8 was comparable in males and females (p = 0.18). The mRNA expression of CYP2C8, CYP2C9, CYP2C19, and CYP3A4, but not CYP2C18, was highly correlated (p < 0.0001). Moreover, the hepatic CYP2C8 and CYP3A4 protein levels were strongly correlated (r = 0.76, p < 0.0001). This correlation is most likely due to common regulation factors for both genes. CYP2C8 mRNA or protein expression levels were not significantly affected by CYP2C8*3 or *4 genotype, gender, or age, and variation observed clinically in CYP2C8 activity warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20190184      PMCID: PMC2879956          DOI: 10.1124/dmd.109.031542

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  31 in total

1.  Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway.

Authors:  D C Zeldin; C R Moomaw; N Jesse; K B Tomer; J Beetham; B D Hammock; S Wu
Journal:  Arch Biochem Biophys       Date:  1996-06-01       Impact factor: 4.013

2.  Sex is a major determinant of CYP3A4 expression in human liver.

Authors:  Renzo Wolbold; Kathrin Klein; Oliver Burk; Andreas K Nüssler; Peter Neuhaus; Michel Eichelbaum; Matthias Schwab; Ulrich M Zanger
Journal:  Hepatology       Date:  2003-10       Impact factor: 17.425

3.  Variability in human cytochrome P450 paclitaxel metabolism.

Authors:  D S Sonnichsen; Q Liu; E G Schuetz; J D Schuetz; A Pappo; M V Relling
Journal:  J Pharmacol Exp Ther       Date:  1995-11       Impact factor: 4.030

4.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

Authors:  T Shimada; H Yamazaki; M Mimura; Y Inui; F P Guengerich
Journal:  J Pharmacol Exp Ther       Date:  1994-07       Impact factor: 4.030

5.  CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.

Authors:  Tanja Busk Bidstrup; Inga Bjørnsdottir; Ulla Grove Sidelmann; Mikael Søndergård Thomsen; Kristian Tage Hansen
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

6.  Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.

Authors:  Elizabeth B Daily; Christina L Aquilante
Journal:  Pharmacogenomics       Date:  2009-09       Impact factor: 2.533

7.  Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes.

Authors:  Judy L Raucy; Lisa Mueller; Kui Duan; Scott W Allen; Stephen Strom; Jerome M Lasker
Journal:  J Pharmacol Exp Ther       Date:  2002-08       Impact factor: 4.030

8.  Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.

Authors:  Elena García-Martín; Carmen Martínez; Beatriz Tabarés; Jesús Frías; José A G Agúndez
Journal:  Clin Pharmacol Ther       Date:  2004-08       Impact factor: 6.875

9.  Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation.

Authors:  B M Kerr; K E Thummel; C J Wurden; S M Klein; D L Kroetz; F J Gonzalez; R H Levy
Journal:  Biochem Pharmacol       Date:  1994-06-01       Impact factor: 5.858

10.  Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide.

Authors:  Mikko Niemi; Julian B Leathart; Mikko Neuvonen; Janne T Backman; Ann K Daly; Pertti J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  2003-10       Impact factor: 6.875

View more
  22 in total

1.  Interindividual variability in hepatic expression of the multidrug resistance-associated protein 2 (MRP2/ABCC2): quantification by liquid chromatography/tandem mass spectrometry.

Authors:  Anand K Deo; Bhagwat Prasad; Larissa Balogh; Yurong Lai; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2012-02-08       Impact factor: 3.922

2.  In vitro characterization of rosiglitazone metabolites and determination of the kinetic parameters employing rat liver microsomal fraction.

Authors:  Leandro Augusto Calixto; Anderson Rodrigo Moraes de Oliveira; Valquíria Aparecida Polisel Jabor; Pierina Sueli Bonato
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-04-17       Impact factor: 2.441

3.  Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5.

Authors:  Rüdiger Kaspera; Suresh B Naraharisetti; Eric A Evangelista; Kristin D Marciante; Bruce M Psaty; Rheem A Totah
Journal:  Biochem Pharmacol       Date:  2011-06-24       Impact factor: 5.858

4.  Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure.

Authors:  Karen Rowland Yeo; Jane R Kenny; Amin Rostami-Hodjegan
Journal:  Eur J Clin Pharmacol       Date:  2013-01-11       Impact factor: 2.953

5.  Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis.

Authors:  Rüdiger Kaspera; Suresh B Naraharisetti; Bani Tamraz; Tariku Sahele; Matthew J Cheesman; Pui-Yan Kwok; Kristin Marciante; Susan R Heckbert; Bruce M Psaty; Rheem A Totah
Journal:  Pharmacogenet Genomics       Date:  2010-10       Impact factor: 2.089

6.  Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis.

Authors:  M Kawaguchi-Suzuki; F Bril; S Kalavalapalli; K Cusi; R F Frye
Journal:  Aliment Pharmacol Ther       Date:  2017-05-03       Impact factor: 8.171

7.  Genetic markers in the EET metabolic pathway are associated with outcomes in patients with aneurysmal subarachnoid hemorrhage.

Authors:  Mark K Donnelly; Yvette P Conley; Elizabeth A Crago; Dianxu Ren; Paula R Sherwood; Jeffery R Balzer; Samuel M Poloyac
Journal:  J Cereb Blood Flow Metab       Date:  2014-11-12       Impact factor: 6.200

8.  Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.

Authors:  Catia Marzolini; Rajith Rajoli; Manuel Battegay; Luigia Elzi; David Back; Marco Siccardi
Journal:  Clin Pharmacokinet       Date:  2017-04       Impact factor: 6.447

Review 9.  Clinical Pharmacokinetics and Pharmacodynamics of Antihyperglycemic Medications in Children and Adolescents with Type 2 Diabetes Mellitus.

Authors:  Fatemeh Akhlaghi; Kelly L Matson; Amir Hooshang Mohammadpour; Meghan Kelly; Asieh Karimani
Journal:  Clin Pharmacokinet       Date:  2017-06       Impact factor: 6.447

Review 10.  PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8.

Authors:  Christina L Aquilante; Mikko Niemi; Li Gong; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2013-12       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.